🗂️
Archived grant — no longer open
This grant has closed and is kept as a historical reference. Browse current grants for active opportunities.
grant
Mechanisms of Resistance and Therapeutic Targets in T-LGL Leukemia
Organization OHIO STATE UNIVERSITYLocation Columbus, UNITED STATESPosted 1 Jan 2024Deadline 31 Dec 2025 ⚠️
NIHUS FederalResearch GrantFY20251-Phosphatidylinositol 3-KinaseActive Follow-upAddressAdverse drug effectAnemiaAntigensApoptosisApoptosis Antigen Ligand 1Apoptosis PathwayApoptoticAutoimmune DiseasesBloodBlood Reticuloendothelial SystemCD178 AntigenCD8CD8BCD8B1CD8B1 geneCD95 LigandCD95 antigen ligandCell BodyCell DeathCell Death InductionCellsCessation of lifeChronicChronic T-Lymphocytic LeukemiaClinicalClinical TrialsClonal ExpansionDataDeathDependenceDevelopmentDiagnosisDifferential Gene ExpressionDiseaseDisorderDoseDrugsExpression SignatureFDA approvedFas LigandFas-LFasL proteinFlow CytofluorometriesFlow CytofluorometryFlow CytometryFlow MicrofluorimetryFlow MicrofluorometryFutureGene ExpressionGene Expression ProfileGene TargetingGenesGenomicsGrowth AgentsGrowth FactorGrowth SubstancesHourIL-15IL15IL15 ProteinImmuneImmunesImmunoglobulin Enhancer-Binding ProteinImmunosuppressantsImmunosuppressive AgentsImmunosuppressive drugImmunosuppressive treatmentIn VitroIndividualInfectionInflammatoryInfusionInfusion proceduresInterleukin-15Interleukin-15 PrecursorIntervention TrialInterventional trialInvestigationLGLLLYT3LaboratoriesLaboratory StudyLarge Cell Granular Lymphogenous LeukemiaLarge Cell Granular Lymphoid LeukemiaLarge Granular Lymphocytic LeukemiaLarge Granular LymphocytosisLeadLeukemic CellMGC9721MediatingMedicationMulti-center trialMulticenter TrialsNF-kBNF-kappa BNF-kappaBNFKBNetwork AnalysisNeutropeniaNuclear Factor kappa BNuclear Transcription Factor NF-kBPI-3 KinasePI3-KinasePI3CGPI3KGammaPI3kPIK3PIK3CGPIK3CG genePathogenesisPathogenicityPathway AnalysisPathway interactionsPatient SelectionPatientsPb elementPeptidesPharmaceutical PreparationsPhase 1/2 Clinical TrialPhase I/II Clinical TrialPhosphatidylinositol 3-KinasePhosphatidylinositol-3-OH KinasePhosphoinositide 3-HydroxykinasePopulationProgrammed Cell DeathProliferatingProteins Growth FactorsPtdIns 3-KinaseReportingResearch SpecimenResistanceRiskSTAT3STAT3 geneSamplingSecondary toSignal PathwaySingle cell seqSpecimenT cell receptor repertoire sequencingT cell receptor sequencingT memory cellT-Cell CLLT-Cell Chronic Lymphocytic LeukemiaT-Cell Chronic Lymphogenous LeukemiaT-Cell Chronic Lymphoid LeukemiaT-Cell Large Granular LymphocyteT-Cell Large Granular Lymphocyte LeukemiaT-Cell Large Granular Lymphocytic LeukemiaT-CellsT-Gamma Lymphoproliferative DisorderT-LGLT-LymphocyteTCR repertoire sequencingTCR sequencingTCR-seqTCRseqTechniquesTechnologyTestingTgamma Large Granular Lymphocyte LeukemiaTimeTissue-Specific Differential Gene ExpressionTissue-Specific Gene ExpressionTranscription Factor NF-kBTransfusionTumor Necrosis Factor Ligand Superfamily Member 6Type I Phosphatidylinositol KinaseType III Phosphoinositide 3-KinaseUpregulationValidationactive followupautoimmune conditionautoimmune disorderautoimmunity diseasechronic T-cell leukemiaclinical remissioncohortcombinatorialcytokinecytopeniacytotoxic CD8 T cellscytotoxic CD8 T lymphocytedeprivationdevelopmentaldrug-related adverse effectsdrug/agenteffective therapyeffective treatmentflow cytophotometryfollow upfollow-upfollowed upfollowupgene expression patterngene expression signatureheavy metal Pbheavy metal leadimmune suppressive agentimmune suppressorimmunogenimmunosuppressive substanceimmunosuppressorin vivoin vivo Modelinfection recurrenceinfusionsinsightkappa B Enhancer Binding Proteinlarge granular lymphocyte leukemialeukemialeukemic transformationmemory T lymphocytenecrocytosisnew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnovelnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeuticsnovel therapynuclear factor kappa betapathwayrecurrent infectionrecurring infectionresistance mechanismresistantresistant mechanismresponders and non-respondersresponders from non-respondersresponders or non-respondersresponders versus non-respondersresponders vs non-respondersresponders/nonrespondersresponsescRNA sequencingscRNA-seqsingle cell RNA-seqsingle cell RNAseqsingle cell expression profilingsingle cell next generation sequencingsingle cell sequencingsingle cell transcriptomic profilingsingle-cell RNA sequencingtargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttherapeutic evaluationtherapeutic targettherapeutic testingthymus derived lymphocytetranscriptional profiletranscriptional signaturetranscriptomicstranslational impactvalidations
Applications closed.
Description preview
ABSTRACT
T-cell large granular lymphocytic leukemia (T-LGLL) is an incurable, underdiagnosed proliferation of clonal CD8+
cytotoxic T-lymphocytes that results in severe neutropenia and anemia, with resultant recurring infections,
transfusion dependence, and death. There are no FDA-approved therapies for T-LGLL, and current immune-
suppressive…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click